格列吡嗪

我司优势生产格列吡嗪；

glipizide    with GMP ，CEP，DMF     CAS：29094-61-9 

Glipizide is an oral rapid- and short-acting anti-diabetic drug from the sulfonylurea class. It is classified as a second generation sulfonylurea, which means that it undergoes enterohepatic circulation. Second-generation sulfonylureas are both more potent and have shorter half-lives than the first-generation sulfonylureas.
Originally available in 1984, it is marketed by Pfizer under the brand name Glucotrol in the USA, where Pfizer sells Glucotrol in doses of 5 and 10 milligrams and Glucotrol XL (an extended release form of glipizide) in doses of 2.5, 5, and 10 milligrams.

Established in May, 2005, Weihai Disu Pharmaceutical Co., Ltd., is a subsidiary of Disha Pharmaceutical Group, and a national high-tech enterprise. Relying on the R&D strength of DiSha Pharmaceutical Group, Weihai DiSu Pharmaceutical Co.,Ltd has eight professional institutes which provide product development, process optimization and other technical services. With outstanding strength in scientific research and technological innovation ,it is a leader in pharmaceutical intermediates, veterinary drug, marine biological products and so on. The company's products strictly enforce the standa